Merck Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by following shareholder, about the loss /misplacement of the share certificate as detailed in the attachment.22-05-2019
22-05-2019
Merck Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by following shareholder, about the loss /misplacement of the share certificates as detailed in the attachment.17-05-2019
This pharma stock has risen over 170% in 17 months
Next week, on Thursday, May 23, Merck will turn ex-dividend for Rs 440 per share, which includes a one-time special dividend of Rs 416 per share on account of gain on business transfer.17-05-2019
Merck Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by our Registrars and Share Transfer Agents, Karvy Fintech Private Limited about the issue of duplicate Share certificate to the shareholder mentioned in the attachment.10-05-2019
Merck Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by the shareholders, about the loss /misplacement of the share certificate as detailed in the attachment.10-05-2019
MERCK LTD. - 500126 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Mr. Aalok Agrawal has been appointed as Additional (Non-Executive) Director of the Company effective June 1, 2019, subject to allotment of Director Identification Number. Mr. Aalok is not related to any Director of the Company. Brief profile of Mr. Aalok Agrawal is given below: Mr. Aalok Agrawal has completed his Bachelor of Science (Physics) from St. Xavier''s College, Mumbai and MBA from Indian Institute of Management, Ahmed a bad. He has been with P&G; for over 20 years with leadership experience on consumer healthcare & FMCG businesses and deep mastery in diverse OTC value creation business models. He has worked in diverse cultural contexts across Europe, North America & Asia/ India and has deep knowledge of go-to-market & commercial environments, competitive environments & healthcare regulation. He is currently Regional Head & Managing Director, Central Eastern Europe, Middle East, Africa- P&G; Personal Healthcare. Mr. Aalok Agrawal is not debarred or disqualified from holding the office of Director by virtue of any order from SEBI / MCA or any such statutory authority. Kindly take the same on record.10-05-2019
MERCK LTD. - 500126 - Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Regulations), 2015, we inform you that Mr. Hon Keong Choo has resigned as Director of the Company effective from closure of business hours on May 10, 2019. Kindly take the above on record and acknowledge the receipt.10-05-2019
Merck Ltd - 500126 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
We would like to inform you that the Company has amended following codes in compliance with the amendments in SEBI (Prohibition of Insider Trading) Regulations, 2015: a. Code of conduct to regulate, monitor and report trading by insiders b. Code of practices and procedures for fair disclosure of unpublished price sensitive information We have enclosed copies of the aforementioned codes. Kindly take the same on record and acknowledge the receipt.10-05-2019
MERCK LTD. - 500126 - Unaudited Financial Results For Quarter Ended March 31, 2019
We are pleased to inform you that at a meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended March 31, 2019 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2019; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2019 furnished by Statutory Auditors of the Company.10-05-2019
MERCK LTD. - 500126 - Notice Of 52Nd Annual General Meeting And Annual Report For The Financial Year 2018 Of Procter & Gamble Health Limited (Formerly Merck Limited)
With reference to the above, please find enclosed herewith the Notice of 52nd Annual General Meeting and Annual Report for the Financial Year 2018 of Procter & Gamble Health Limited (formerly Merck Limited).08-05-2019